A phase 2 trial of pemetrexed and cisplatin followed sequentially by gefitinib versus pemetrexed and cisplatin in Asian 'never smoker' patients with advanced non-small cell lung cancer

Trial Profile

A phase 2 trial of pemetrexed and cisplatin followed sequentially by gefitinib versus pemetrexed and cisplatin in Asian 'never smoker' patients with advanced non-small cell lung cancer

Completed
Phase of Trial: Phase II

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Gefitinib (Primary) ; Cisplatin; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Therapeutic Use
  • Sponsors Eli Lilly
  • Most Recent Events

    • 01 Aug 2012 Primary endpoint 'Progression-free-survival-duration' has not been met.
    • 01 Jul 2010 Status changed from active, no longer recruiting to completed as reported by ClinicalTrials.gov.
    • 06 Jun 2010 Results presented at the 46th Annual Meeting of the American Society of Clinical Oncology.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top